AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

One of the better-quality companies in the pharmaceutical sector, AbbVie ( ABBV 2.35%) had a phenomenal year in 2025.

UnitedHealth Group, Inc’s. UNH Optum Rx is expanding its offerings for patients with the introduction of two additional HUMIRA biosimilars. Effective Jul 1, Optum Rx will offer three biosimilar ...

Prescription medication is a lifeline for millions of people around the U.S. Unfortunately, the cost of such medications has ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent cliff.

The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...

ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...

Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...